144 related articles for article (PubMed ID: 8387346)
1. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.
Riccardi A; Danova M; Paccagnella A; Giordano M; Favaretto A; Panozzo M; Ghiotto C; Comis S; Fiorentino M; Chieco-Bianchi L
Ann Hematol; 1993 Apr; 66(4):185-93. PubMed ID: 8387346
[TBL] [Abstract][Full Text] [Related]
2. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
[TBL] [Abstract][Full Text] [Related]
3. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Paccagnella A; Favaretto A; Riccardi A; Danova M; Ghiotto C; Giordano M; Pappagallo G; Comis S; Panozzo M; Chieco-Bianchi L
Cancer; 1993 Aug; 72(3):697-706. PubMed ID: 8392903
[TBL] [Abstract][Full Text] [Related]
5. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow.
Orazi A; Cattoretti G; Schiró R; Siena S; Bregni M; Di Nicola M; Gianni AM
Blood; 1992 May; 79(10):2610-9. PubMed ID: 1586713
[TBL] [Abstract][Full Text] [Related]
7. Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer.
Danova M; Rosti V; Mazzini G; De Renzis MR; Locatelli F; Cazzola M; Riccardi A; Ascari E
Int J Cancer; 1995 Nov; 63(5):646-51. PubMed ID: 7591280
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
9. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.
Eguchi K; Kabe J; Kudo S; Mano K; Morinari H; Nakada K; Noda K; Saito Y; Tanaka T; Uzawa T
Cancer Chemother Pharmacol; 1994; 34(1):37-43. PubMed ID: 8174201
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human granulocyte macrophage-colony stimulating factor in long-term marrow cultures from patients with aplastic anemia.
Martínez-Jaramillo G; Gómez-Morales E; Mayani H
Am J Hematol; 1999 Jun; 61(2):107-14. PubMed ID: 10367789
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
[TBL] [Abstract][Full Text] [Related]
13. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
[TBL] [Abstract][Full Text] [Related]
14. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in Hodgkin's disease.
Oza AM; Leahy M; Dorey E; Davis CL; Amess J; Horton M; Rohatiner AZ; Wrigley PF; Lister TA
Hematol Oncol; 1991; 9(6):337-47. PubMed ID: 1748400
[TBL] [Abstract][Full Text] [Related]
16. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
Tjan-Heijnen VC; Biesma B; Festen J; Splinter TA; Cox A; Wagener DJ; Postmus PE
J Clin Oncol; 1998 Aug; 16(8):2708-14. PubMed ID: 9704721
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
Ho AD; Del Valle F; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Haas R; Thiel E; Andreesen R; Fiedler W
Cancer; 1990 Aug; 66(3):423-30. PubMed ID: 2194641
[TBL] [Abstract][Full Text] [Related]
18. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
Broxmeyer HE; Cooper S; Williams DE; Hangoc G; Gutterman JU; Vadhan-Raj S
Exp Hematol; 1988 Aug; 16(7):594-602. PubMed ID: 3260558
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1 alpha and soluble interleukin-2 receptor during small cell lung cancer chemotherapy: comparison of high chemotherapy dose with rhGM-CSF and standard chemotherapy dose without rhGM-CSF.
Gautier V; Pujol JL; Michel FB
Lung Cancer; 1995 Oct; 13(2):145-53. PubMed ID: 8581394
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Madero L; Díaz MA; Ortega JJ; Olive T; Martínez A; Badell I; Muñoz A; Gómez P
Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]